Radiosensitizer — Drug Enhancing Radiation Therapy

In formal oncology practice, a radiosensitizer is defined as a chemical or pharmacological agent that amplifies the lethal effects of ionizing radiation on tumour cells. Ionizing radiation functions primarily by generating free radicals that induce lethal deoxyribonucleic acid (DNA) double-strand breaks. Radiosensitizers interfere with cellular survival mechanisms, for instance by inhibiting DNA damage repair pathways, promoting oxygenation within hypoxic tumour cores, or synchronizing the cell cycle into its most radiation-sensitive phases (such as the G2/M phase).

Historically, standard cytotoxic chemotherapy drugs have served as conventional radiosensitizers. However, contemporary oncology also incorporates targeted molecular compounds, hypoxic cell sensitisers, and advanced nanomaterials designed specifically to accumulate within neoplastic tissues. The clinical objective remains maximizing the therapeutic ratio: increasing tumour cell kill without causing an unacceptable increase in normal tissue toxicity.

Understanding radiosensitizers helps patients appreciate why their treatment schedule might involve receiving a drug infusion or tablet shortly before their radiotherapy session. This synchronized approach can feel demanding, but timing is crucial to ensure the drug is active in tumour cells during irradiation. Being aware of this synergy also helps individuals anticipate and manage combined side effects. Discussing these agents with the clinical team enables shared decision-making regarding treatment intensity, symptom control, and potential trial options.

Radiosensitizers themselves are not measured through diagnostic blood tests, but their application depends on diagnostic imaging and pathology. Contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans evaluate tumour vascularity and hypoxia. In glioblastoma, testing for MGMT promoter methylation helps predict the sensitising efficacy of alkylating agents like temozolomide combined with radiation.

Radiosensitizers are frequently employed in locally advanced solid tumours where radiotherapy forms the backbone of curative-intent treatment. They are standard in cervical cancer, where cisplatin acts as a potent sensitiser. They are also widely used in head and neck squamous cell carcinomas, glioblastoma (using temozolomide), locally advanced rectal cancer (using fluoropyrimidines), oesophageal cancer, and non-small cell lung cancer.

When a radiosensitizer is prescribed, treatment protocols are carefully synchronized. Chemotherapy agents such as cisplatin, fluorouracil, or capecitabine are administered on specific schedules alongside external beam radiotherapy. Targeted agents like cetuximab may also serve this purpose. Patients receive detailed instructions regarding hydration, anti-sickness medications, and the timing of doses relative to radiation appointments.